<div id="readability-page-1"><p>Decheng Capital LLC lowered its holdings in  4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.6% during the second quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 239,510 shares of the company's stock after selling 96,005 shares during the quarter. 4D Molecular Therapeutics accounts for  0.2% of Decheng Capital LLC's holdings, making the stock its 19th largest holding. Decheng Capital LLC owned 0.52% of 4D Molecular Therapeutics worth $889,000 as of its most recent SEC filing.</p><p>A number of other hedge funds have also modified their holdings of the business. Quadrature Capital Ltd acquired a new stake in shares of  4D Molecular Therapeutics during the 2nd quarter worth about $42,000.  Los Angeles Capital Management LLC purchased a new position in  4D Molecular Therapeutics during the second quarter worth about $42,000.  Dynamic Technology Lab Private Ltd purchased a new position in  4D Molecular Therapeutics during the first quarter worth about $39,000.  AQR Capital Management LLC acquired a new stake in shares of  4D Molecular Therapeutics during the first quarter valued at about $46,000.  Finally, Russell Investments Group Ltd. purchased a new stake in shares of  4D Molecular Therapeutics in the 1st quarter valued at approximately $63,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>4D Molecular Therapeutics Stock Performance</h2><p>Shares of FDMT opened at $10.70 on Thursday. 4D Molecular Therapeutics, Inc. has a 1 year low of $2.23 and a 1 year high of $12.34. The stock has a market capitalization of $611.34 million, a PE ratio of -2.85 and a beta of 2.96. The stock has a 50-day simple moving average of $10.27 and a 200-day simple moving average of $6.96. </p><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The firm had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.40 million.  Analysts predict that  4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>FDMT has been the subject of several research reports. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a report on Friday, November 7th. Royal Bank Of Canada lifted their price objective on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, November 11th. Wall Street Zen upgraded 4D Molecular Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Roth Capital decreased their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, August 12th. Finally, Leerink Partners  reaffirmed an &#34;outperform&#34; rating and issued a $17.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Eight analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $28.70.</p><p><b>Check Out Our Latest Research Report on FDMT</b></p><h2>Insider Activity at 4D Molecular Therapeutics</h2><p>In other news, insider Scott Bizily sold 2,678 shares of the firm's stock in a transaction on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the sale, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. This trade represents a 42.70% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 10,763 shares of company stock valued at $109,415. Corporate insiders own  9.60% of the company's stock. </p><h2>About 4D Molecular Therapeutics</h2> (Free Report)<p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than 4D Molecular Therapeutics</li><li>Trading Halts Explained</li><li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li><li>Using the MarketBeat Dividend Tax Calculator</li><li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>3 Stocks You’ll Wish You Bought Before 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkRNVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkRNVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FDMT

<p>Decheng Capital LLC reduced its holdings in 4D Molecular Therapeutics by 28.6% in Q2. The stock opened at $10.70, with a 1-year range of $2.23-$12.34. Analysts forecast growth, with mixed ratings and a target price of $28.70. Insider Scott Bizily sold shares, decreasing his position by 42.70%. 4D Molecular Therapeutics develops genetic medicines in ophthalmology, cardiology, and pulmonology.</p>

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC